Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant / Impacto de las puntaciones del riesgo en los resultados de los pacientes con neoplasias mieloides tras el trasplante alogénico de células madre
175 patients were evaluated. With a median (range) follow-up of 3.96 (0.3217.22) years, the 5-year probabilities (95% CI) of OS, CIR, NRM, and GRFS were 36% (28%44%), 28% (21%35%), 38% (30%46%) and 24% (17%31%), respectively. For OS, only the DRI score selected two groups with statistically significant differences (DRI 01 41% vs. DRI ≥2 24%; p=0.011). The combination of DRI 01 and HCT-CI 02 showed OS probabilities of 45% vs. 26% for those with DRI 01 and HCT-CI ≥3; p=0.041.
Conclusions:
In patients with AML and MDS submitted to allo-transplant, the combination of HCT-CI and DRI scores provided the best stratification for OS. (AU)